-
Overview
As a premier project delivery service provider in Asia's pharmaceutical sector, we cover the entire spectrum from project origination to construction management, as well as validation for research and development (R&D) labs, factories, and medical company office buildings in Singapore, Malaysia, and China.
Over 30 years, we have delivered top-notch pharmaceutical, biotechnology, and life science facilities across Asia, the United States, and Europe, totalling over $13 Billion (USD) in projects.
Our global expertise embraces a deep understanding of local procedures, regulations, and production systems. We endeavour to offer a full range of project and construction management services, ensuring compliance with international safety and quality standards in every country we operate.
A solid global track record in the life sciences sector
Lendlease has established an impressive track record, marked by successful collaborations with prominent pharmaceutical and life sciences industry giants. Our proven expertise and determined commitment have helped us establish partnerships with some of the world's notable and leading pharmaceutical companies. These include:
- Abbott
- Abbvie
- Amgen
- AstraZeneca
- Bayer
- Baxter
- Bristol-Myers-Squibb
- GSK
- Johnson & Johnson
- Lonza
- MSD
- Novartis
- Pfizer
- Roche
These partnerships stand as a testament to our ability to navigate the intricate landscape of the pharmaceutical and life sciences realm, delivering exceptional outcomes that transcend expectations. Lendlease's collaborative approach and in-depth understanding of the life science sector's unique challenges and requirements firmly position us as a trusted partner to advance healthcare and scientific research and developments.
-
At a glance
In China
Lendlease has been a prominent player in the life sciences business since it entered the Chinese market in 1993. We have forged strong and enduring customer relationships with leading international life science companies, delivering numerous high-quality projects to our clients.
To date, Lendlease has delivered over 350 projects of production plants, utilities, and various other project types, comprising more than 2 million sqm of R&D and office space in total.
In 2021, a third-party research agency's report revealed outstanding customer satisfaction and recommendation scores of 9.3 and 9.7 points, respectively, underscoring our consistent commitment to excellence in project delivery and customer service.
In SingaporeLendlease is the cornerstone of Singapore's biotechnology realm, having developed over 90% of Tuas Biomedical Park's biotechnology facilities. Our integral role in constructing Singapore's premier pharmaceutical complexes is underscored by clients entrusting us with future expansions and enhancements.
A prime example is the Lonza Plant 1 biologics facility, a replica of its existing plant in Portsmouth, New Hampshire, USA. The three-floor, 26,000m2 life science facility features four 20,000L bio-reactor trains. Our meticulous execution saw nearly 1,000 equipment pieces, extensive piping, and 19,000 I/O points installed within 24 months. The project received the SHARP Award from the Singapore Workplace Health and Safety Council.
In 2022, Lendlease completed a strategic partnership with PGGM, the Netherlands' second-largest pension fund. This collaboration resulted in a robust S$1 billion industrial investment fund dedicated to high-tech innovation and the life sciences sector across Australia, Japan, and Singapore.
-
Our Expertise
Team
- Our robust team in China blends local expertise with a collaborative One Team Culture, ensuring seamless cooperation for successful project delivery.
- With 85% of our members boasting invaluable Pharma experience, our Life Science projects benefit from unparalleled insights
- Moreover, 70% of our experts are senior engineers, demonstrating our commitment to excellence.
Client-centric Approach
- Our Fast Track and Cost-Focused Project Capabilities deliver efficient and economical solutions. Our clients’ needs are prioritized, resulting in exceptional results with speed and cost-effectiveness at the core.
Design Contribution
- Our deep-rooted design and build heritage maximizes project value through pre-construction services.
- Constructability Reviews during business and design stages offer intimate insights, driving tailored solutions for efficiency, cost-effectiveness, and quality, exceeding expectations.
Execution Strategy
- Meticulous planning precedes our seamless construction-led delivery approach.
- Best Value Procurement emphasizes transparency and governance-based practices for optimal results.
- Timely and accurate reporting empowers informed decisions, converging planning, execution, and procurement to achieve excellence.
-
Awards
Merck Asia Pacific 2021 Safety Award
This award is testament to Lendlease's long-term service excellence to its customers and a recognition of Lendlease's uncompromising safety, transparency, focus and introspection. This is also the result of Lendlease's joint efforts in the Asia-Pacific region over the past 15 years.
Safety and Health Award Recognition for Projects (SHARP Award)Amgen Waste Water Treatment Project, 2021
Safety and Health Award Recognition for Projects (SHARP Award)Amgen MSB Project, 2019
International Society of Pharmaceutical Engineering (ISPE) Facility of the YearGenetech ECP-1 facility, 2021
As a premier project delivery service provider in Asia's pharmaceutical sector, we cover the entire spectrum from project origination to construction management, as well as validation for research and development (R&D) labs, factories, and medical company office buildings in Singapore, Malaysia, and China.
Over 30 years, we have delivered top-notch pharmaceutical, biotechnology, and life science facilities across Asia, the United States, and Europe, totalling over $13 Billion (USD) in projects.
Our global expertise embraces a deep understanding of local procedures, regulations, and production systems. We endeavour to offer a full range of project and construction management services, ensuring compliance with international safety and quality standards in every country we operate.
A solid global track record in the life sciences sector
Lendlease has established an impressive track record, marked by successful collaborations with prominent pharmaceutical and life sciences industry giants. Our proven expertise and determined commitment have helped us establish partnerships with some of the world's notable and leading pharmaceutical companies. These include:
- Abbott
- Abbvie
- Amgen
- AstraZeneca
- Bayer
- Baxter
- Bristol-Myers-Squibb
- GSK
- Johnson & Johnson
- Lonza
- MSD
- Novartis
- Pfizer
- Roche
These partnerships stand as a testament to our ability to navigate the intricate landscape of the pharmaceutical and life sciences realm, delivering exceptional outcomes that transcend expectations. Lendlease's collaborative approach and in-depth understanding of the life science sector's unique challenges and requirements firmly position us as a trusted partner to advance healthcare and scientific research and developments.
In China
Lendlease has been a prominent player in the life sciences business since it entered the Chinese market in 1993. We have forged strong and enduring customer relationships with leading international life science companies, delivering numerous high-quality projects to our clients.
To date, Lendlease has delivered over 350 projects of production plants, utilities, and various other project types, comprising more than 2 million sqm of R&D and office space in total.
In 2021, a third-party research agency's report revealed outstanding customer satisfaction and recommendation scores of 9.3 and 9.7 points, respectively, underscoring our consistent commitment to excellence in project delivery and customer service.
In Singapore
Lendlease is the cornerstone of Singapore's biotechnology realm, having developed over 90% of Tuas Biomedical Park's biotechnology facilities. Our integral role in constructing Singapore's premier pharmaceutical complexes is underscored by clients entrusting us with future expansions and enhancements.
A prime example is the Lonza Plant 1 biologics facility, a replica of its existing plant in Portsmouth, New Hampshire, USA. The three-floor, 26,000m2 life science facility features four 20,000L bio-reactor trains. Our meticulous execution saw nearly 1,000 equipment pieces, extensive piping, and 19,000 I/O points installed within 24 months. The project received the SHARP Award from the Singapore Workplace Health and Safety Council.
In 2022, Lendlease completed a strategic partnership with PGGM, the Netherlands' second-largest pension fund. This collaboration resulted in a robust S$1 billion industrial investment fund dedicated to high-tech innovation and the life sciences sector across Australia, Japan, and Singapore.
Team
- Our robust team in China blends local expertise with a collaborative One Team Culture, ensuring seamless cooperation for successful project delivery.
- With 85% of our members boasting invaluable Pharma experience, our Life Science projects benefit from unparalleled insights
- Moreover, 70% of our experts are senior engineers, demonstrating our commitment to excellence.
Client-centric Approach
- Our Fast Track and Cost-Focused Project Capabilities deliver efficient and economical solutions. Our clients’ needs are prioritized, resulting in exceptional results with speed and cost-effectiveness at the core.
Design Contribution
- Our deep-rooted design and build heritage maximizes project value through pre-construction services.
- Constructability Reviews during business and design stages offer intimate insights, driving tailored solutions for efficiency, cost-effectiveness, and quality, exceeding expectations.
Execution Strategy
- Meticulous planning precedes our seamless construction-led delivery approach.
- Best Value Procurement emphasizes transparency and governance-based practices for optimal results.
- Timely and accurate reporting empowers informed decisions, converging planning, execution, and procurement to achieve excellence.
This award is testament to Lendlease's long-term service excellence to its customers and a recognition of Lendlease's uncompromising safety, transparency, focus and introspection. This is also the result of Lendlease's joint efforts in the Asia-Pacific region over the past 15 years.
Amgen Waste Water Treatment Project, 2021
Amgen MSB Project, 2019
Genetech ECP-1 facility, 2021
Meet our people
-
Lvjun GongHead of Project Management & Construction, China
Gong has more than 20 years of experience in the construction business and has been with Lendlease since 2008. He has extensive project and delivery experience, with strong track records among life science and industrial clients. Gong has been a strong leader in driving Lendlease’s customer-focus framework as well as practical Environment, Health and Safety implementation for construction.
What are you most interested in?
Contact us directly via the form below and a member from our team will reach out. We look forward to hearing from you.